EUVIMEDEUVIMED entdecken
Open Access

Targeting the liver clock improves fibrosis by restoring TGF-β signaling

Emilie Crouchet, Mayssa Dachraoui, Frank Jühling, Natascha Roehlen, Marine A Oudot, Sarah C Durand, Clara Ponsolles, Cloé Gadenne, Laura Meiss-Heydmann, Julien Moehlin, Romain Martin, Nicolas Brignon und 18 weitere

Journal of Hepatology · 2025-01 · 82 (1) · 120-133

DOI: 10.1016/j.jhep.2024.07.034 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Hepatology, 2025-01. Verfasst von Emilie Crouchet und 29 weiteren Autor:innen. Beteiligte Einrichtung: University of Strasbourg, Inserm, Institute for Translational Medicine and Liver Disease (ITM), UMR_S1110, Strasbourg, France. Hauptthemen laut MEDLINE: Liver Cirrhosis, Transforming Growth Factor beta, Hepatic Stellate Cells, Signal Transduction. Die Arbeit wurde bisher 70-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: European Research Council, Japan Agency for Medical Research and Development, Centre National de la Recherche Scientifique.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Liver fibrosis is the major driver of hepatocellular carcinoma and liver disease-related death. Approved antifibrotic therapies are absent and compounds in development have limited efficacy. Increased TGF-β signaling drives collagen deposition by hepatic stellate cells (HSCs)/myofibroblasts. Here, we aimed to dissect the role of the circadian clock (CC) in controlling TGF-β signaling and liver fibrosis. METHODS: Using CC-mutant mice, enriched HSCs and myofibroblasts obtained from healthy and fibrotic mice in different CC phases and loss-of-function studies in human hepatocytes and myofibroblasts, we investigated the relationship between CC and TGF-β signaling. We explored hepatocyte-myofibroblast communication through bioinformatic analyses of single-nuclei transcriptomes and performed validation in cell-based models. Using mouse models for MASH (metabolic dysfunction-associated steatohepatitis)-related fibrosis and spheroids from patients with liver disease, we performed proof-of-concept studies to validate pharmacological targetability and clinical translatability. RESULTS: We discovered that the CC oscillator temporally gates TGF-β signaling and this regulation is broken in fibrosis. We demonstrate that HSCs and myofibroblasts contain a functional CC with rhythmic expression of numerous genes, including fibrogenic genes. Perturbation studies in hepatocytes and myofibroblasts revealed a reciprocal relationship between TGF-β activation and CC perturbation, which was confirmed in patient-derived ex vivo and in vivo models. Pharmacological modulation of CC-TGF-β signaling inhibited fibrosis in mouse models in vivo as well as in patient-derived liver spheroids. CONCLUSION: The CC regulates TGF-β signaling, and the breakdown of this control is associated with liver fibrosis in patients. Pharmacological proof-of-concept studies across different models have uncovered the CC as a novel therapeutic target for liver fibrosis - a growing unmet medical need. IMPACT AND IMPLICATIONS: Liver fibrosis due to metabolic diseases is a global health challenge. Many liver functions are rhythmic throughout the day, being controlled by the circadian clock (CC). Here we demonstrate that regulation of the CC is perturbed upon chronic liver injury and this perturbation contributes to fibrotic disease. By showing that a compound targeting the CC improves liver fibrosis in patient-derived models, this study provides a novel therapeutic candidate strategy to treat fibrosis in patients. Additional studies will be needed for clinical translation. Since the findings uncover a previously undiscovered profibrotic mechanism and therapeutic target, the study is of interest for scientists investigating liver disease, clinical hepatologists and drug developers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver CirrhosisTransforming Growth Factor betaHepatic Stellate CellsSignal TransductionCircadian ClocksMyofibroblastsAnimalsMiceHumansDisease Models, AnimalHepatocytesMaleLiver

Stichwörter der Autor:innen

Liver diseaseMASLDcircadian clockdrug discoveryhepatic stellate cellstranscriptional regulation

Substanzen

Transforming Growth Factor beta

Autor:innen und Institutionen

  • University of Strasbourg, Inserm, Institute for Translational Medicine and Liver Disease (ITM), UMR_S1110, Strasbourg, France.
  • University of Strasbourg, Inserm, Institute for Translational Medicine and Liver Disease (ITM), UMR_S1110, Strasbourg, France; Department of Medicine II, Gastroenterology, Hepatology, Endocrinology and Infectious Diseas…
  • University of Strasbourg, Inserm, Institute for Translational Medicine and Liver Disease (ITM), UMR_S1110, Strasbourg, France; ÆPIC Animal Facility Platform, University of Strasbourg, Inserm UMR_S1110, Strasbourg, Franc…
  • Department of Gastroenterology, NHO Kure Medical Center and Chugoku Cancer Center, Kure, Japan.
  • Hiroshima Prefectural Hospital, Hiroshima, Japan.
  • Hiroshima Institute of Life Sciences, Hiroshima, Japan; Center for Medical Specialist Graduate Education and Research, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.

Förderung

  • European Research Council
  • Japan Agency for Medical Research and Development
  • Centre National de la Recherche Scientifique
  • British Skin Foundation
  • Deutsches Krebsforschungszentrum
  • Scripps Research
  • Institut National de la Santé et de la Recherche Médicale
  • European Commission

Zitieren

APA

Crouchet, E., Dachraoui, M., Jühling, F., Roehlen, N., Oudot, M. A., Durand, S. C., Ponsolles, C., Gadenne, C., Meiss-Heydmann, L., Moehlin, J., Martin, R., Brignon, N., Del Zompo, F., Teraoka, Y., Aikata, H., Abe-Chayama, H., Chayama, K., Saviano, A., Heide, D., …, & Baumert, T. F. (2025). Targeting the liver clock improves fibrosis by restoring TGF-β signaling. Journal of Hepatology, 82(1), 120-133. https://doi.org/10.1016/j.jhep.2024.07.034

Vancouver

Crouchet E, Dachraoui M, Jühling F, Roehlen N, Oudot MA, Durand SC, et al. Targeting the liver clock improves fibrosis by restoring TGF-β signaling. Journal of Hepatology. 2025;82(1):120-133. doi:10.1016/j.jhep.2024.07.034

BibTeX
@article{Crouchet2025,
  author = {Crouchet, Emilie and Dachraoui, Mayssa and Jühling, Frank and Roehlen, Natascha and Oudot, Marine A and Durand, Sarah C and Ponsolles, Clara and Gadenne, Cloé and Meiss-Heydmann, Laura and Moehlin, Julien and Martin, Romain and Brignon, Nicolas and Del Zompo, Fabio and Teraoka, Yuji and Aikata, Hiroshi and Abe-Chayama, Hiromi and Chayama, Kazuaki and Saviano, Antonio and Heide, Danijela and Onea, Mihaela and Geyer, Lucas and Wolf, Thibaut and Felli, Emanuele and Pessaux, Patrick and Heikenwälder, Mathias and Chambon, Pierre and Schuster, Catherine and Lupberger, Joachim and Mukherji, Atish and Baumert, Thomas F},
  title = {Targeting the liver clock improves fibrosis by restoring TGF-β signaling},
  journal = {Journal of Hepatology},
  year = {2025},
  volume = {82},
  number = {1},
  pages = {120--133},
  doi = {10.1016/j.jhep.2024.07.034}
}
Kostenlos starten →